Jefferies London: BeOne Medicines announced a phase 3 success for its HER2 bispecific today in gastric cancer. John Oyler walks us through that and the whole pipeline
- Nov 17, 2025
- 1 min read
He hit on earnings, the HER2, degraders, and what BeOne is looking for in potential partners.
Coverage brought to you by















.png)

